Rossari Biotech Intrinsic Value
ROSSARI • Chemicals
Current Stock Price
₹444.05
Primary Intrinsic Value
₹319.68
Market Cap
₹488.5 Cr
+100.0%
Upside
Median Value
₹888.10
Value Range
₹171 - ₹1110
Assessment
Trading Below Calculated Value
Safety Margin
50.0%
ROSSARI Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹319.68 | ₹255.74 - ₹383.62 | -28.0% | EPS: ₹26.64, Sector P/E: 12x |
| Book Value Method | asset | ₹1077.27 | ₹969.54 - ₹1185.00 | +142.6% | Book Value/Share: ₹1077.27, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹888.10 | ₹799.29 - ₹976.91 | +100.0% | Revenue/Share: ₹2138.18, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹888.10 | ₹799.29 - ₹976.91 | +100.0% | EBITDA: ₹296.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹1110.12 | ₹888.10 - ₹1332.14 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹170.50 | ₹153.45 - ₹187.55 | -61.6% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹219.51 | ₹197.56 - ₹241.46 | -50.6% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹888.10 | ₹799.29 - ₹976.91 | +100.0% | ROE: 12.5%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹803.57 | ₹723.21 - ₹883.93 | +81.0% | EPS: ₹26.64, BVPS: ₹1077.27 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
ROSSARI Intrinsic Value Analysis
What is the intrinsic value of ROSSARI?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Rossari Biotech (ROSSARI) is ₹888.10 (median value). With the current market price of ₹444.05, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹170.50 to ₹1110.12, indicating ₹170.50 - ₹1110.12.
Is ROSSARI undervalued or overvalued?
Based on our multi-method analysis, Rossari Biotech (ROSSARI) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.99 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 12.5% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 12.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.24x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Rossari Biotech
Additional stock information and data for ROSSARI
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹137 Cr | ₹46 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹43 Cr | ₹-9 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹152 Cr | ₹62 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹29 Cr | ₹-121 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹48 Cr | ₹30 Cr | Positive Free Cash Flow | 8/10 |